Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.4
Astrana Health, Inc. amended credit facility of $400.0 million with Truist Bank at subject to a spread based on the Company's leverage ratio maturing June 16, 2026.
- Instrument
- credit facility
- Principal
- $400.0 million
- Counterparty
- Truist Bank
- Rate
- subject to a spread based on the Company's leverage ratio
- Maturity
- June 16, 2026
- Event
- amendment
Exact text from the filing
The Credit Agreement Amendment does not change the amount of the Revolving Line of Credit (which remains at $400.0 million), the maturity date of the Revolving Line of Credit (which remains June 16, 2026), or the rate of interest paid on the Revolving Line of Credit (which remains subject to a spread based on the Company's leverage ratio).
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Astrana Health, Inc. incurred term loan of up to $300.0 million, with $180.0 million funded at the closing with Truist Bank at Term SOFR Reference Rate plus a spread from 1.50% to 2.75% maturing November 3, 2028.
- Instrument
- term loan
- Principal
- up to $300.0 million, with $180.0 million funded at the closing
- Counterparty
- Truist Bank
- Rate
- Term SOFR Reference Rate plus a spread from 1.50% to 2.75%
- Maturity
- November 3, 2028
- Event
- incurrence
Exact text from the filing
The Credit Agreement Amendment provides a new term loan to the Company in an aggregate amount of up to $300.0 million, with $180.0 million funded at the closing of the Credit Agreement Amendment, and $120.0 million available to be drawn by the Company as delayed draw loans during the six months subsequent to the closing of the Credit Agreement Amendment (collectively, the "New Term Loan").
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Astrana Health, Inc. amended Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement with Truist Bank, as administrative agent, and the banks and other financial institutions party thereto valued at $300.0 million, with $180.0 million funded at the closing (effective 2023-11-03).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Truist Bank, as administrative agent, and the banks and other financial institutions party thereto
- Value
- $300.0 million, with $180.0 million funded at the closing
- Effective
- 2023-11-03
Exact text from the filing
On November 3, 2023, Apollo Medical Holdings, Inc. (the “Company”) entered into a Third Amendment to Amended and Restated Credit Agreement and Incremental Agreement (the “Credit Agreement Amendment”) with the banks and other financial institutions party thereto and Truist Bank, as administrative agent (the “Administrative Agent”), which amends the Amended and Restated Credit Agreement, dated as of June 16, 2021, entered into among the Company, the lenders party thereto and the Administrative Agent (as amended, the “Credit Agreement”). The Credit Agreement Amendment provides a new term loan to the Company in an aggregate amount of up to $300.0 million, with $180.0 million funded at the closing of the Credit Agreement Amendment
View on SEC.gov